In ELISA experiments (including sandwich ELISA, indirect ELISA, etc.), non-specific interference mainly stems from antibody cross-reactivity, adsorption of impurities in sample matrices, and background signals from reagents. This interference can lead to false-positive or false-negative results. Reducing such interference requires targeted design across multiple dimensions,
including reagent optimization, sample processing, and operational control. Specific methods are as follows:
Antibodies are the core of ELISA specificity, and strict screening and optimization are needed to minimize non-specific binding:
Prioritize monoclonal antibodies (which target a single epitope and have low cross-reactivity) or affinity-purified polyclonal antibodies (to remove non-specific antibodies). Avoid using crude antiserum, which contains large
amounts of non-target antibodies.
Verify antibody cross-reactivity in pre-experiments: Use molecules with high homology to the target antigen (e.g., family
proteins, isomers) as controls. If the detection signal is <5% of the target antigen signal, the antibody can be deemed specific.
Determine the optimal working concentration of antibodies via checkerboard titration (e.g., 1–5 μg/mL for capture
antibodies, 0.5–2 μg/mL for detection antibodies): Excessively high concentrations increase non-specific adsorption,
while excessively low concentrations result in weak signals.
Shorten antibody incubation time (e.g., 1–2 hours at 37°C instead of overnight at 4°C) or lower the incubation temperature
to reduce non-specific binding between antibodies and non-target molecules (ensure the efficiency of target binding
is not affected).
For polyclonal antibodies, pre-incubate with an excess of non-target antigens (e.g., homologous proteins with no cross-reactivity to the target antigen) to block potential cross-reactive sites in the antibodies. Alternatively, use F(ab’)₂ fragment
antibodies
Impurities in samples (e.g., proteins, lipids, enzymes) are major sources of interference and require pretreatment to reduce their impact:
Serum/plasma samples: If hemolysis (interference from hemoglobin) or lipemia (lipid adsorption of antibodies) occurs, centrifuge first (12,000 rpm × 10 minutes) to remove precipitates. Alternatively, use commercial serum purification kits (e.g., protein A/G affinity columns) to remove high-abundance proteins (e.g., albumin, IgG) and reduce matrix competition for binding.
Cell lysates/tissue homogenates: Add protease inhibitors (e.g., PMSF, protease inhibitor cocktails) to prevent antigen degradation. Use detergents (e.g., 0.1% Triton X-100) to solubilize membrane proteins and avoid impurity precipitation. If necessary, use ultracentrifugation (100,000 × g × 30 minutes) to remove cell debris.
Dilute samples (urine/cerebrospinal fluid): If sample concentration is too low and requires concentration, use ultrafiltration tubes (3–10 kDa molecular weight cutoff) for concentration. Avoid excessive salt concentrations (desalt via dialysis afterward)
to prevent salt ions from interfering with antigen-antibody binding.
Diluents should contain blocking agents (e.g., 1%–5% BSA, 5%–10% fetal bovine serum) to reduce non-specific adsorption of
impurities in samples. Add stabilizers (e.g., 0.05% Tween-20, 0.02% sodium azide) to prevent antigen denaturation or
microbial contamination.
For serum samples, use a "serum matrix without the target antigen" (e.g., healthy human serum diluent) as the diluent to avoid non-specific signals caused by matrix differences (i.e., "matrix matching").
The plastic surface of ELISA plates and impurities in reagents easily adsorb antibodies or enzyme conjugates, requiring thorough blocking and washing to prevent this:
Select effective blocking agents: Common options include 5% non-fat milk powder (suitable for most antibodies,
low cost) or 1%–2% BSA (suitable for phosphorylated antigens and hydrophilic antigens, reducing cross-reactivity).
If background signals persist, try adding 0.05% Tween-20 or 0.1% fish gelatin to enhance blocking.
Control blocking time and temperature: Incubate at 37°C for 1–2 hours or overnight at 4°C to ensure the blocking agent
fully covers the blank sites on the plate well surface. Avoid overly short blocking times (<30 minutes), which result in incomplete blocking.
Washing buffer formulation: Use PBS containing 0.05% Tween-20 (PBST). Tween-20 disrupts non-specific hydrophobic
binding while stabilizing antigen-antibody complexes. Avoid using high-concentration Tween-20 (>0.1%), which may
disrupt target binding.
Standardize washing parameters: Use a washing volume of ≥300 μL per well (ensure complete replacement of liquid in the well) and wash at least 3 times. After each wash, blot dry on absorbent paper (to avoid residual liquid diluting subsequent reagents). Prioritize using an automated plate washer to avoid inconsistencies in manual washing intensity or frequency.
The activity of enzyme conjugates and the stability of chromogenic substrates affect non-specific signals and require strict control:
Select high-purity enzyme conjugates: For example, HRP (horseradish peroxidase)- or AP (alkaline phosphatase)-labeled secondary antibodies. Ensure labeling efficiency (enzyme/antibody molar ratio of 1:1–1:5) and remove free enzyme
residues (via gel filtration purification if needed).
Control enzyme conjugate concentration: Determine the optimal dilution ratio (typically 1:1000–1:10,000) via pre-experiments. Excessively high concentrations increase non-specific adsorption, while excessively low concentrations
result in weak signals. After incubation, wash thoroughly to remove unbound enzyme conjugates.
Prepare chromogenic substrates fresh: For example, TMB substrate (used with HRP) should be stored protected from light and prepared immediately before use to avoid oxidation (which causes blue background). PNPP substrate (used with AP) should be protected from heavy metal ion contamination (which affects enzyme activity).
Strictly control chromogenic time: Determine the optimal chromogenic duration (typically 5–30 minutes) via pre-experiments. Terminate the reaction immediately when the positive control shows a clear color and the negative control shows no color. Use a sufficient volume of stop solution (e.g., 2 M H₂SO₄, 50–100 μL per well) to ensure complete termination of the reaction and prevent further color development.
A control system helps quickly identify non-specific interference and adjust experimental conditions in a timely manner:
Blank control: Contains only diluent and chromogenic reagents (no antibodies or samples), used to monitor reagent background (OD value should be <0.15; otherwise, reagent contamination is indicated).
Negative control: Samples known to lack the target antigen (e.g., healthy human serum, blank cell lysates), used to monitor non-specific signals from the sample matrix (OD value should be <10% of the positive control).
Blocking control: Pre-incubate detection antibodies with an excess of unlabeled target antigen before adding the sample.
If the signal is reduced by ≥80% compared to normal detection, the original signal is specific binding (otherwise, it is non-specific).
If the negative control shows an excessively high signal, use the "replacement method" to identify the source: Replace antibodies, samples, or enzyme conjugates separately, observe changes in signal, and locate the interference source (e.g., if the signal decreases after sample replacement, the sample contains interfering substances).
For samples suspected of interference, perform gradient dilution: If the rate of decrease in non-specific signals with dilution is consistent with that of the target signal, the interference is caused by non-specific adsorption. In this case, enhance blocking or purify the sample.
ELISA plate selection: Prioritize high-binding ELISA plates (e.g., polystyrene plates, suitable for most protein antigens)
or specially treated plates (e.g., aminated, carboxylated plates) based on antigen properties to reduce non-specific
adsorption of antigens.
Clean operating environment: Disinfect the experimental bench with 75% ethanol to avoid reagent contamination by dust or microorganisms. Use disposable, enzyme-free, pyrogen-free pipette tips to prevent cross-contamination.
Through the above methods, non-specific interference can be systematically reduced from three perspectives—"reducing
interference sources," "blocking binding pathways," and "verifying signal specificity"—ensuring the accuracy and reliability
of ELISA experimental results.
